More easily find the right patients and quickly move to recruitment and regulatory acceptance with QIAGEN Real-World Insights (RWI)
The prevalence of cancer biomarkers detected in the laboratory differs from what is observed at the bedside. Real-world data helps you better understand the actual numbers of patients with a particular cancer type and where and for which biomarkers they are being tested.
Providing information on current molecular testing trends, QIAGEN RWI allows for an expanded view of cancer indications to be evaluated for your drug for maximum reach and success.
Knowing where cancer patients are being tested and for which biomarkers can help design and market more effective clinical trials. With QIAGEN RWI, you can:
QIAGEN’s RWI portfolio combines robust real-world data from over 160,000 cancer cases and advanced analytics to achieve better decisions faster in early drug and test development.
To access RWI, you can:
Do you have novel questions, hypotheses, and hurdles to overcome? Our team of scientists, bioinformaticists, and clinicians can help you strategize, customize, and deliver within your timeline.
Choose the best biomarkers and cancer indications for your molecularly targeted therapies
Identify appropriate patient cohorts and enhance your CDx design to improve stratification and success
Expand beyond the one biomarker, one drug paradigm with expert molecular profiling and drug-response analyses